Vineet Laboratories P/E Ratio
Current P/E Ratio
65.24
High Valuation
Very High - High growth expectations or significantly overvalued
Vineet Laboratories P/E ratio. Vineet Laboratories (VINEETLAB) P/E ratio is 65.24 (High), EPS (TTM) ₹1.00, current price ₹36.52 on NSE — Very High - High growth expectations or significantly overvalued. Check Vineet Laboratories market cap to track the company's total market size over time.
Current Valuation Metrics
P/E Ratio
65.24
Current Price
₹36.52
EPS (TTM)
₹1.00
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
55.62
Sector Median
31.61
Sector Rank
#11 of 199
Sector Percentile
5.5%
VINEETLAB P/E Ratio — Valuation Signal & Historical Context
Vineet Laboratories P/E 65.24 — signal: Overvalued. Also explore VINEETLAB price trends to track price trends across different timeframes.
- Stock appears overvalued with PE of 65.24, suggesting caution for new investments
- Trading at premium to sector average PE of 55.62
VINEETLAB vs Healthcare Peers — P/E Ratio Comparison
Vineet Laboratories P/E 65.24 vs Healthcare average 55.62, median 31.61 — range 2.04–740.29.
Sector Average
55.62
Sector Median
31.61
Lowest P/E
2.04
Highest P/E
740.29
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.28 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 4.78 | ₹65 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹46 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |